Novoxel seeks to pre-empt MRSA drug concerns.

The article reports that the company Novoxel has presented data showing that the drug NXL101 destroys potentially problematic strains of Methicillin Resistant Staphylococcus Aureus (MRSA). The drug is manufactured by the company. The data was presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) that was held in Munich, Germany. The drug offers an alternative treatment option in the case of fluoroquinolone resistance.